ERBB2 and breast cancer: Sensitivity analyses performed on the subpopulation treated for BC only, treated with anti-ERBB2 drugs only, and with an explicit exposure declaration identified similar pregnancy and/or fetal or newborn outcome profiles, with a significant overreporting of oligohydramnios and neonatal kidney failure (eFigures 7 and 8 in Supplement 1).